Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial
Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2019.05.095
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2020
Authors
Publisher
Elsevier BV